Please choose your application, enter the information requested below. * Marked fields are mandatory.
Product Description
Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.
IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)
Target: PPARα/γ
Aleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones.
Information
CAS No475479-34-6
FormulaC24H23NO5S
Clinical Informationclinicalinformation
PathwayCell Cycle/DNA Damage
TargetPPAR
Specifications
Purity / Grade>98%
Solubility10 mM in DMSO
Smilessmiles
Misc Information
Alternative NamesR1439;RO0728804
Observed Molecular Weight437.51
related data
Get valuable resources and offers directly to your email.